Brevan Howard Capital Management LP Makes New $228,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Brevan Howard Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 10,144 shares of the company’s stock, valued at approximately $228,000.

A number of other large investors also recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics in the 4th quarter valued at $97,000. BNP Paribas Financial Markets acquired a new stake in shares of Enliven Therapeutics in the 4th quarter valued at $112,000. ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter worth $200,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after acquiring an additional 1,275 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $18.51 on Monday. The firm’s 50 day moving average price is $19.06 and its two-hundred day moving average price is $21.99. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The stock has a market cap of $908.21 million, a PE ratio of -9.74 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the sale, the insider now directly owns 997,688 shares in the company, valued at approximately $16,032,846.16. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total transaction of $122,606.13. Following the completion of the transaction, the chief operating officer now directly owns 309,976 shares of the company’s stock, valued at $5,700,458.64. This trade represents a 2.11% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,111 shares of company stock worth $1,493,145. Insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.